State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors

Oni J. Blackstock, Karen H. Wang, David A. Fiellin

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


BACKGROUND: In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications. OBJECTIVE: To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care. DESIGN: Cross-sectional survey of 53 state and territorial ADAP formularies. MAIN MEASURES: ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as "consistent" with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as "partially consistent". ADAPs without coverage were categorized as "no coverage". KEY RESULTS: Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%). CONCLUSIONS: Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.

Original languageEnglish (US)
Pages (from-to)1426-1433
Number of pages8
JournalJournal of general internal medicine
Issue number12
StatePublished - Dec 2011
Externally publishedYes


  • AIDS
  • AIDS drug assistance program
  • HIV
  • cardiovascular disease
  • public assistance

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors'. Together they form a unique fingerprint.

Cite this